2-(methylthio)-4-(2-phenyl-1H-imidazol-1-yl)pyrimidine | 591754-07-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(methylthio)-4-(2-phenyl-1H-imidazol-1-yl)pyrimidine
• 英文别名: 2-methylsulfanyl-4-(2-phenylimidazol-1-yl)pyrimidine
• CAS: 591754-07-3
• 化学式: C₁₄H₁₂N₄S
• 分子量: 268.342
• InChiKey: WKDLAARKJYJVPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  68.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(methylthio)-4-(2-phenyl-1H-imidazol-1-yl)pyrimidine 在 sodium tungstate 、 双氧水 作用下， 以 乙酸乙酯 为溶剂， 以91%的产率得到2-(methylsulfonyl)-4-(2-phenyl-1H-imidazol-1-yl)pyrimidine
  参考文献：
  名称：

  2,4-Disubstituted pyrimidines: A novel class of KDR kinase inhibitors

  摘要：

  2,4-Disubstituted pyrimidines were synthesized as a novel class of KDR kinase inhibitors. Evaluation of the SAR of the screening lead compound 1 (KDR IC50 = 105 nM, Cell IC50 = 8% inhibition at 500 nM) led to the potent 3,5-dimethylaniline derivative 2d (KDR IC50 = 6 nM, cell IC50 = 19 nM). (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00244-0
• 作为产物：
  描述：

  2-苯基咪唑 、 2-甲硫基-4-氯嘧啶 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以43%的产率得到2-(methylthio)-4-(2-phenyl-1H-imidazol-1-yl)pyrimidine
  参考文献：
  名称：

  2,4-Disubstituted pyrimidines: A novel class of KDR kinase inhibitors

  摘要：

  2,4-Disubstituted pyrimidines were synthesized as a novel class of KDR kinase inhibitors. Evaluation of the SAR of the screening lead compound 1 (KDR IC50 = 105 nM, Cell IC50 = 8% inhibition at 500 nM) led to the potent 3,5-dimethylaniline derivative 2d (KDR IC50 = 6 nM, cell IC50 = 19 nM). (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00244-0

文献信息

• [EN] TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE
  申请人：MERCK & CO INC

  公开号：WO2003011836A1

  公开（公告）日：2003-02-13

  The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

  本发明涉及抑制、调节和/或调节酪氨酸激酶信号转导的化合物，包含这些化合物的组合物，以及使用它们治疗哺乳动物的酪氨酸激酶依赖性疾病和状况，例如血管生成、癌症、肿瘤生长、动脉硬化、年龄相关性黄斑变性、糖尿病性视网膜病变、炎症性疾病等的方法。
• Tyrosine kinase inhibitors
  申请人：——

  公开号：US20040220201A1

  公开（公告）日：2004-11-04

  The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

  本发明涉及抑制、调节和/或调节酪氨酸激酶信号转导的化合物，含有这些化合物的组合物以及使用它们治疗哺乳动物中的酪氨酸激酶依赖性疾病和病况的方法，例如血管生成、癌症、肿瘤生长、动脉粥样硬化、年龄相关性黄斑变性、糖尿病视网膜病变、炎症性疾病等。
• US6958340B2
  申请人：——

  公开号：US6958340B2

  公开（公告）日：2005-10-25
• 2,4-Disubstituted pyrimidines: A novel class of KDR kinase inhibitors
  作者：Peter J. Manley、Adrienne E. Balitza、Mark T. Bilodeau、Kathleen E. Coll、George D. Hartman、Rosemary C. McFall、Keith W. Rickert、Leonard D. Rodman、Kenneth A. Thomas

  DOI：10.1016/s0960-894x(03)00244-0

  日期：2003.5

  2,4-Disubstituted pyrimidines were synthesized as a novel class of KDR kinase inhibitors. Evaluation of the SAR of the screening lead compound 1 (KDR IC50 = 105 nM, Cell IC50 = 8% inhibition at 500 nM) led to the potent 3,5-dimethylaniline derivative 2d (KDR IC50 = 6 nM, cell IC50 = 19 nM). (C) 2003 Elsevier Science Ltd. All rights reserved.